|
|
HOMER3 |
homer scaffold protein 3 |
- Neurexins and neuroligins
- Neurexins and neuroligins
|
|
|
|
|
IHO1 |
interactor of HORMAD1 1 |
|
|
|
|
|
MEOX2 |
mesenchyme homeobox 2 |
|
|
|
|
|
MORN3 |
MORN repeat containing 3 |
|
|
|
|
|
MYO5A |
myosin VA |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Regulation of actin dynamics for phagocytic cup formation
- Insulin processing
- FCGR3A-mediated phagocytosis
- Regulation of MITF-M-dependent genes involved in pigmentation
- Regulation of MITF-M-dependent genes involved in pigmentation
|
|
- Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
|
|
|
OTUD6A |
OTU deubiquitinase 6A |
|
|
|
|
|
PAK1 |
p21 (RAC1) activated kinase 1 |
- Generation of second messenger molecules
- Regulation of actin dynamics for phagocytic cup formation
- FCERI mediated MAPK activation
- FCERI mediated MAPK activation
- CD28 dependent Vav1 pathway
- EPHB-mediated forward signaling
- Ephrin signaling
- Sema3A PAK dependent Axon repulsion
- Activation of RAC1
- Signal transduction by L1
- Smooth Muscle Contraction
- VEGFR2 mediated vascular permeability
- CD209 (DC-SIGN) signaling
- RHO GTPases activate PKNs
- RHO GTPases Activate ROCKs
- RHO GTPases activate PAKs
- RHO GTPases activate PAKs
- MAPK6/MAPK4 signaling
- G beta:gamma signalling through CDC42
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOQ GTPase cycle
- RHOH GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOV GTPase cycle
|
|
|
|
|
PKIA |
cAMP-dependent protein kinase inhibitor alpha |
|
- 3,5-Diiodotyrosine
- Hydroxyfasudil
- (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine
- (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE
- (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
- (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE
- N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
- (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
- 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE
- (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
- (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
- (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- H-89
- 5-(2-methylpiperazine-1-sulfonyl)isoquinoline
- N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE
- 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
- 3-pyridin-4-yl-1H-indazole
- 5-benzyl-1,3-thiazol-2-amine
- 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
- 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
- 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium
- Fasudil
- Myristic acid
- A-674563
- 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE
- Y-27632
|
|
|
|
PKIG |
cAMP-dependent protein kinase inhibitor gamma |
|
|
|
|
|
RASGRP3 |
RAS guanyl releasing protein 3 |
- Activation of RAS in B cells
- Activation of RAS in B cells
- RAF/MAP kinase cascade
|
|
|
|
|
REDIC1 |
regulator of DNA class I crossover intermediates 1 |
|
|
|
|
|
SKAP1 |
src kinase associated phosphoprotein 1 |
|
|
|
|
|
SMCP |
sperm mitochondria associated cysteine rich protein |
|
|
|
|
|
SPAG8 |
sperm associated antigen 8 |
|
|
|
|
|
THAP10 |
THAP domain containing 10 |
|
|
|
|
|
TPPP |
tubulin polymerization promoting protein |
|
|
|
|
|
XIAP |
X-linked inhibitor of apoptosis |
- Activation of caspases through apoptosome-mediated cleavage
- SMAC (DIABLO) binds to IAPs
- SMAC (DIABLO) binds to IAPs
- SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
- SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
- SMAC, XIAP-regulated apoptotic response
- Deactivation of the beta-catenin transactivating complex
- RIPK1-mediated regulated necrosis
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NF-kappa-B signaling pathway
- Regulation of necroptotic cell death
- Regulation of PTEN localization
- Regulation of PTEN stability and activity
- Regulation of the apoptosome activity
|
- 1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide
- Dequalinium
- N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE
- AEG35156
- Terpinen-4-ol
|
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
|
|
|
ZAR1 |
zygote arrest 1 |
|
|
|